Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:10/5/2009

ery strong immune system, have a very potent inflammatory response, seemingly more active than in young children or older adults. Although it seems illogical, their overactive inflammatory response may put these individuals at higher risk to serious disease due to the damage it causes in trying to eliminate the virus infection.

Influenza vaccines activate immune responses in people that can last for a long time. For a vaccinated individual the vaccine induced immune response can act quickly to stop the reproduction of the virus, limit the spread of the virus and quickly prevent significant virus damage. Currently there are two types of influenza vaccines, a live vaccine and a killed vaccine. A person receiving the Flumist live vaccine is infected with a weakened mixture of influenza viruses that cannot cause serious disease but they activate the immune response to produce T cells that make cytokines to activate T cells and other white blood cells that will kill influenza infected cells and stimulate antibody production. Other influenza vaccines use inactivated virus or the H1 and N1 proteins of the virus to immunize a person and produce only antibodies against the virus. These vaccines take approximately 10 days to produce a protective immune response.

CEL-SCI's DENDRITIC H1N1 TREATMENT

CEL-SCI's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients, utilizes the unique LEAPS vaccine technology to convert an individual's white blood cells into cells targeted to killing influenza. The treatment is based on CEL-SCI's L.E.A.P.S. technology. LEAPS vaccines are small proteins that combine a piece of an influenza protein with a small activator protein. The combined protein activates the dendritic cell, a white blood - cell, which presents the influenza protein to the T cell and then tells that T cell with a focused, controlled amount of cytokine, to grow and make the cytokines ne
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2